GBS Global Biopharma, Inc.
BioTech/Drugs - N/A, N/A, N/A
GBS Global Biopharma, Inc. Employees
GBS Global Biopharma, Inc. Senior Management
GBS Global Biopharma, Inc. Details
GbS Global Biopharma ("GbS"), the wholly-owned Canadian subsidiary of GB Sciences, Inc. (OTCQB:GBLX), is a plant-based research and biopharma drug development company. Our goal is to create patented formulations of plant-inspired, optimized therapeutic mixtures (OTM) for the prescription drug market to treat a variety of conditions. The 'plant-inspired' active ingredients in our OTM are synthetic homologues identical to the original plant compounds, but produced synthetically under cGMP manufacturing controls. GbS' novel drug discovery platform has yielded 5 issued US and 3 issued international patents, as well as 19 US and 40 international patent-pending applications. In our drug development pipeline, GbS has five preclinical stage programs, and our lead Parkinson's disease therapeutic program is being prepared for a First-in-Man clinical trial. In addition to Parkinson's disease, Gb is developing therapeutics for chronic pain, COVID-related cytokine release syndrome (CRS), Mast Cell Activation Syndrome (MCAS), anxiety, depression, and heart failure. GbS' productive research and development network includes nine universities, several hospitals, and Contract Research Organizations.
GBS Global Biopharma, Inc. Technologies
Captcha
reCAPTCHA
Email Providers
Gmail
Load Balancers
Apache
Fonts
Google Font API
Other
Google Apps
Hosting
GoDaddy Hosting